BRF
ADMS

B. Riley Financial’s Adamas Pharmaceuticals ADMS Stock Holding History

B. Riley Financial’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-21,000
Closed -$712K – 341
2017
Q4 		$712K Buy
+21,000
New +$586K 0.19% 126

Other funds holding ADMS

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BWCA
Brenner West Capital Advisors New York $804M AUM 16.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

B. Riley Financial's ADMS Position: Q1 2018 in Review

B. Riley Financial sold out of Adamas Pharmaceuticals (ADMS) in Q1 2018, closing a stake of 21,000 shares — an estimated $712K sold.

B. Riley Financial first reported a position in ADMS in Q4 2017 and held it in 1 quarter. The position peaked at $712K in Q4 2017. 118 funds tracked by Wall St. Rank hold ADMS as of Q1 2018.

  • B. Riley Financial reported no remaining Adamas Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • B. Riley Financial sold 21,000 Adamas Pharmaceuticals shares in Q1 2018, an estimated $712K.
  • B. Riley Financial first reported a position in Adamas Pharmaceuticals in Q4 2017 and held it in 1 quarter.
  • B. Riley Financial's Adamas Pharmaceuticals position peaked at $712K in Q4 2017.
  • 118 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q1 2018.

Based on B. Riley Financial's 13F filing for Q1 2018, filed 4 May 2018.